Last edition
News about "Insilico Medicine"
Insilico Medicine and Ribo Partner on AI-Powered RNA Therapeutics Development
Insilico Medicine and Ribo partner to accelerate RNA interference and oligonucleotide drug development using Artificial Intelligence (AI)I-powered discovery platforms and automated laboratory technologies.
Insilico Medicine | 13/05/2026 | By News Bureau
Eli Lilly Eyes USD 2 Billion AI Drug Discovery Deal with Insilico Medicine
Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.
Insilico Medicine | 30/03/2026 | By Darshana | 144
Insilico Medicine Launches PandaClaw AI Platform for Drug Discovery
Insilico Medicine launches PandaClaw AI platform to accelerate drug discovery, enabling real-time analysis, target identification and disease hypothesis generation through an intuitive natural language interface.
Insilico Medicine | 24/03/2026 | By News Bureau | 124
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Insilico Medicine | 09/03/2026 | By News Bureau | 188
Insilico Medicine Receives USD 5 Million from Menarini
Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.
Insilico Medicine | 05/02/2026 | By News Bureau | 117
Insilico Medicine and Qilu Pharmaceutical Sign USD 120 Million Cardiometabolic Drug Deal
According to the agreement, Insilico Medicine will utilise its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.
Insilico Medicine | 28/01/2026 | By News Bureau | 142
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Insilico Medicine | 21/01/2026 | By News Bureau | 216
Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery
The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.
Insilico Medicine | 11/11/2025 | By Dineshwori | 444
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy